drugset / Trial / NCT05814718

Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT

NCT05814718

RandomizedParallel-groupSingle-blindTreatment

Summary

A multicenter randomized study on the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with carmustine, etoposide, and cytarabine (modified BEAM protocol) in the pretreatment of T-cell lymphoma underwent autologous stem cell transplantation

Timeline

Start
2023-04-15
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 100 mg/m2 Intravenous
Subject Cytarabine Small molecule 200 mg/m2 Intravenous
Subject Mel Unknown 140 mg/m2
Subject Mitoxantrone Small molecule 24 mg/m2 Intravenous
Background Etoposide Small molecule 200 mg/m2 Intravenous
Background carmustine Small molecule 300 mg/m2 Intravenous